EVC
IRD

Eidelman Virant Capital’s Opus Genetics IRD Stock Holding History

Eidelman Virant Capital’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$51K Hold
25,000
– – 0.04% 164
2022
Q2 		$48K Buy
+25,000
New +$56.8K 0.03% 175

Other funds holding IRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return

Eidelman Virant Capital's IRD Position: Q3 2022 in Review

Eidelman Virant Capital held its Opus Genetics (IRD) position steady in Q3 2022 at 25,000 shares worth $51K. The position accounts for 0.04% of the portfolio, ranked #164.

Eidelman Virant Capital first reported a position in IRD in Q2 2022 and has held it in 2 quarters since. 37 funds tracked by Wall St. Rank hold IRD as of Q3 2022.

  • Eidelman Virant Capital held 25,000 shares of Opus Genetics worth $51K as of Q3 2022.
  • Eidelman Virant Capital left its Opus Genetics share count unchanged in Q3 2022.
  • Opus Genetics made up 0.04% of Eidelman Virant Capital's portfolio in Q3 2022, its #164 holding.
  • Eidelman Virant Capital first reported a position in Opus Genetics in Q2 2022 and has held it in 2 quarters since.
  • 37 funds tracked by Wall St. Rank held Opus Genetics as of Q3 2022.

Based on Eidelman Virant Capital's 13F filing for Q3 2022, filed 25 Oct 2022.